866-997-4948(US-Canada Toll Free)

Thymus Cancer - Pipeline Review, H1 2013

Published By :

Global Markets Direct

Published Date : Apr 2013

Category :

Cancer

No. of Pages : 37 Pages


Global Markets Directs, \'Thymus Cancer - Pipeline Review, H1 2013\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Thymus Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Thymus Cancer. 

Thymus Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Thymus Cancer.
  • A review of the Thymus Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Thymus Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Thymus Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Thymus Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Thymus Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Thymus Cancer 7
Thymus Cancer Therapeutics under Development by Companies 9
Thymus Cancer Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Thymus Cancer Therapeutics - Products under Development by Companies 13
Thymus Cancer Therapeutics - Products under Investigation by Universities/Institutes 14
Companies Involved in Thymus Cancer Therapeutics Development 15
TopoTarget A/S 15
Nerviano Medical Sciences S.r.l. 16
Thymus Cancer - Therapeutics Assessment 17
Assessment by Monotherapy Products 17
Assessment by Combination Products 18
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Drug Profiles 23
belinostat - Drug Profile 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
milciclib - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
alvocidib + romidepsin - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Allogeneic Tumor Cell Vaccine + [celecoxib] + [cyclophosphamide] - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Thymus Cancer Therapeutics - Drug Profile Updates 30
Thymus Cancer Therapeutics - Dormant Products 34
Thymus Cancer - Product Development Milestones 35
Featured News & Press Releases 35
May 17, 2012: Topotarget Presents Phase I/II Clinical Data Of Belinostat At ASCO 2012 35

Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Table


Number of Products Under Development for Thymus Cancer, H1 2013 7
Products under Development for Thymus Cancer - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Mid Clinical Stage Development, H1 2013 11
Comparative Analysis by Early Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 14
Nerviano Medical Sciences S.r.l., H1 2013 16
Assessment by Monotherapy Products, H1 2013 17
Assessment by Combination Products, H1 2013 18
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Stage and Molecule Type, H1 2013 22
Thymus Cancer Therapeutics - Drug Profile Updates 30
Thymus Cancer Therapeutics - Dormant Products 34

List of Chart


Number of Products under Development for Thymus Cancer, H1 2013 7
Products under Development for Thymus Cancer - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Mid Clinical Stage Products, H1 2013 11
Early Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 17
Assessment by Combination Products, H1 2013 18
Assessment by Route of Administration, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 20
Assessment by Molecule Type, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *